STAA

STAAR Surgical's stock has been impacted by several key events in the past six months. Preliminary Q1 2026 revenue exceeding $90 million led to a surge in its stock price, attributed to robust demand in China and continued sales growth in the Americas. The FDA approved an expanded age range for its EVO/EVO+ Visian Implantable Collamer Lenses, expected to broaden the potential U.S. market. However, the company faced challenges in 2025, with revenue declining by 23.7%, primarily due to a drop in the Asia Pacific region. Profitability also worsened, leading some analysts to maintain a "Sell" rating on the stock in early 2026. In January 2026, the company underwent a governance reset following the rejection of an all-cash merger with Alcon. As of May 8, 2026, the stock price had risen but experienced a loss over the preceding four weeks.